New therapy for pulmonary hypertension using prostaglandin I2 incorporated nanoparticles

2015 Fiscal Year Final Research Report

• Project/Area Number: 26860563
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Cardiovascular medicine
• Research Institution: Okayama University
• Principal Investigator: AKAGI Satoshi 岡山大学, 医歯(薬)学総合研究科, 助教 (60601127)
• Project Period (FY): 2014-04-01 – 2016-03-31
• Keywords: ベラプロスト封入ナノ粒子 / sugen/hypoxiaラット / モノクロタリンラット / 気管内投与 / 肺高血圧

Outline of Final Research Achievements

We prepare the beraprost incorporated nanoparticles (BPS-NPs) and investigated the effects on pulmonary hypertension in Sugen-hypoxia and monocrotaline rat models of pulmonary arterial hypertension (PAH). We examined the right ventricular systolic pressure (RVSP), right ventricular hypertrophy (RVH) and pulmonary vascular remodeling 2 weeks after the intratracheal administration of PBS, FITC incorporated nanoparticle (FITC-NPs) and BPS-NPs. BPS-NPs significantly decreased RVSP, RVH and pulmonary vascular remodeling compared with PBS and FITC-NPs in Sugen-hypoxia and monocrotaline rat models. Furthermore, BPS-NPs significantly improved survival rate compared with PBS and FITC-NPs in monocrotaline rat models.

Free Research Field

循環器内科学